PCI Biotech update

Core Insights - PCI Biotech is currently evaluating a new bioprocessing technology under a material transfer agreement, with no financial terms disclosed [1] - The company's future is heavily dependent on the ongoing technology evaluation, and there are currently no discussions regarding strategic alternatives [2] - The liquidity position of PCI Biotech is critical, raising doubts about its ability to continue as a going concern [2] - The management structure has been streamlined, with only the CEO position remaining in the parent company, while the subsidiary has opted not to have a CEO [3] Company Overview - PCI Biotech is a biopharmaceutical company focused on developing and commercializing new technologies and therapies through its photochemical technology platform, which is based on research from Oslo University Hospital [4] - The technology platform includes two main areas: Photochemical lysis (PCL) for enhancing yield and purity in viral vector manufacturing, and Photochemical internalization (PCI) for enabling light-triggered endosomal release [4]